186:. The plaintiffs appealed the dismissal in the Ninth Circuit Court of Appeals. The Ninth Circuit granted oral argument which was held on Friday, January 17, 2014. On March 7, 2014, the Ninth Circuit affirmed the dismissal of the class action, Catoosa Fund LP v. Medivation, Inc., No. 12-15960. The Ninth Circuit stated "With the exception of the tenuous and unattributed statement that Dr. Schneider relates secondhand, plaintiff has not pled any facts supporting an inference of actual knowledge by defendants. Plaintiff relies heavily on the inference that, due to their positions, the defendants must have known about the unmatched nature of the study. That inference is entirely speculative and does not rise to the required strong inference; plaintiff's allegation is not at least as compelling as any opposing inference one could draw from the facts alleged."
27:
171:
was initiated by Izard Nobel LLP, alleging that
Medivation made false and misleading statements regarding the effectiveness of Dimebon as a treatment for Alzheimer's disease, before being revealed that it did not meet primary and secondary goals in a Phase 3 trial for patients with mild to moderate
523:
represents investors in
Applestein v. Medivation, Inc., No. 10-CV-00998 (EMC) (N.D. Cal.), in which plaintiffs allege that defendants inflated the price of Medivation stock by making false statements concerning the efficacy of its chief drug's treatment of Alzheimer's
493:
represents investors in
Applestein v. Medivation, Inc., No. 10-CV-00998 (EMC) (N.D. Cal.), in which plaintiffs allege that defendants inflated the price of Medivation stock by making false statements concerning the efficacy of its chief drug's treatment of Alzheimer's
736:
771:
214:. AstraZeneca was reported to weigh in with an offer of £7 billion ($ 10 billion). On April 29, Sanofi launched a $ 9.3 billion takeover offer which was rejected by the Medivation board.
228:
announced that it would acquire the company for $ 14 billion or $ 81.50 per share, a 21% premium over the closing price on August 19; the acquisition was completed
September 28, 2016.
766:
741:
304:
746:
159:
and David Hung founded
Medivation in 2003. After watching a 28-year-old breast cancer patient die during his oncology fellowship David Hung said he must do something about it.
167:
On March 3, 2010, Medivation's stock dropped $ 27.15 per share to close at $ 13.10, a 67% one-day decline on volume of 45 million shares. In response, a security fraud
726:
721:
115:
company focused on development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation was headquartered in
731:
413:
476:
444:
756:
506:
609:
761:
138:(enzalutamide) capsules for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received
308:
119:, California, beginning operations in December 2004 with the acquisition of Medivation Neurology, Inc. Its final CEO was David Hung.
131:
352:
660:
624:
130:
for multiple stages of prostate cancer and for breast cancer. On August 31, 2012, Medivation and
Astellas announced that the
536:
330:
183:
148:
announced it would acquire the company in August 2016 for $ 14 billion and completed the acquisition in
October 2016.
256:
378:
569:
595:
37:
688:
Medivation. "Medivation CEO David Hung Named
National EY Entrepreneur Of The Year 2014 Overall Award Winner
421:
480:
451:
687:
168:
510:
544:
156:
78:
237:
74:
386:
195:
112:
751:
207:
417:
305:"Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Medivation, Inc"
180:
179:
were initially David
Applestein then Catoosa Fund, LP. On March 22, 2012, the case was
176:
715:
282:
116:
56:
414:"The Brualdi Law Firm, P.C. Announces Class Action Lawsuit Against Medivation, Inc"
135:
127:
26:
548:
642:
199:
194:
In April, the company was linked with a number of potential acquirers including
674:
390:
139:
260:
581:
123:
610:"AstraZeneca eyes Xtandi windfall with potential £7B bid for Medivation"
218:
445:"Class action complaint for violation of the federal securities laws"
225:
211:
145:
88:
661:"Pfizer to Acquire Medivation for $ 14B - GEN News Highlights - GEN"
450:. Northern District of California: Izard Nobel LLP. Archived from
203:
704:
142:. XTANDI is an oral, once-daily androgen receptor inhibitor.
307:. Law Offices of Howard G. Smith. 2010-03-03. Archived from
99:
240:
was the EY Entrepreneur of the Year 2014 National Winner.
737:
Technology companies based in the San
Francisco Bay Area
625:"Medivation Rejects Sanofi's $ 9.3 Billion Takeover Bid"
175:
The counsel for the case was Bernstein Liebhard and the
675:"Pfizer to buy cancer drug firm Medivation for $ 14bn"
772:
Defunct pharmaceutical companies of the United States
623:
Joshua Jamerson and Noemie Bisserbe (29 April 2016).
94:
84:
68:
51:
43:
33:
443:Robbins Geller Rudman & Dowd (March 9, 2010).
221:and Genentech, which ultimately lost to Pfizer.
690:Medivation.com. Medivation, 17 December 2014.
596:"Sanofi could go hostile with Medivation bid"
8:
767:Pharmaceutical companies established in 2004
742:Biotechnology companies of the United States
331:"Pfizer Completes Acquisition of Medivation"
19:
747:Biotechnology companies established in 2004
379:"Pfizer to Buy Medivation for $ 14 Billion"
25:
18:
408:
406:
509:. Bernstein Liebhard LLP. Archived from
479:. Bernstein Liebhard LLP. Archived from
727:Companies formerly listed on the Nasdaq
248:
722:American companies established in 2004
582:"Unpublished Dispositions (Memoranda)"
541:Securities class action clearinghouse
353:"Nothing ventured, something gained?"
7:
377:Rockoff, Jonathan D. (2016-08-23).
210:, and a possible hostile bid from
122:Medivation, in collaboration with
16:American biopharmaceutical company
14:
132:U.S. Food and Drug Administration
732:Companies based in San Francisco
547:. March 22, 2012. Archived from
570:Ninth Circuit. Court of Appeals
420:March 12, 2010. Archived from
1:
757:2016 mergers and acquisitions
643:"Medivation call for offers"
259:. Medivation. Archived from
762:Biopharmaceutical companies
677:. BBC News. 22 August 2016.
163:2010 – Class action lawsuit
788:
134:(FDA) granted approval to
24:
126:, was in development of
38:Pharmaceutical industry
172:Alzheimer's disease.
507:"U. SETH OTTENSOSER"
257:"Investor relations"
169:class-action lawsuit
551:on 16 December 2013
545:Stanford Law School
383:Wall Street Journal
357:www.bizjournals.com
217:Other suitors were
21:
513:on 28 January 2013
477:"Michael S. Bigin"
663:. 22 August 2016.
537:"Medivation, Inc"
311:on 10 August 2014
283:"Management team"
113:biopharmaceutical
106:
105:
779:
708:
707:
705:Official website
691:
685:
679:
678:
671:
665:
664:
657:
651:
650:
639:
633:
632:
620:
614:
613:
606:
600:
599:
598:. 13 April 2016.
592:
586:
585:
578:
572:
567:
561:
560:
558:
556:
533:
527:
526:
520:
518:
503:
497:
496:
490:
488:
483:on 24 April 2012
473:
467:
466:
464:
462:
456:
449:
440:
434:
433:
431:
429:
410:
401:
400:
398:
397:
374:
368:
367:
365:
363:
349:
343:
342:
340:
338:
333:. Yahoo! Finance
327:
321:
320:
318:
316:
301:
295:
294:
292:
290:
279:
273:
272:
270:
268:
253:
111:was an American
102:
29:
22:
20:Medivation, Inc.
787:
786:
782:
781:
780:
778:
777:
776:
712:
711:
703:
702:
699:
694:
686:
682:
673:
672:
668:
659:
658:
654:
649:. 29 July 2016.
641:
640:
636:
622:
621:
617:
608:
607:
603:
594:
593:
589:
580:
579:
575:
568:
564:
554:
552:
535:
534:
530:
516:
514:
505:
504:
500:
486:
484:
475:
474:
470:
460:
458:
457:on 3 March 2016
454:
447:
442:
441:
437:
427:
425:
412:
411:
404:
395:
393:
376:
375:
371:
361:
359:
351:
350:
346:
336:
334:
329:
328:
324:
314:
312:
303:
302:
298:
288:
286:
281:
280:
276:
266:
264:
255:
254:
250:
246:
236:Medivation CEO
234:
208:Gilead Sciences
192:
177:lead plaintiffs
165:
154:
152:Company history
98:
71:
64:
60:
17:
12:
11:
5:
785:
783:
775:
774:
769:
764:
759:
754:
749:
744:
739:
734:
729:
724:
714:
713:
710:
709:
698:
697:External links
695:
693:
692:
680:
666:
652:
634:
615:
601:
587:
573:
562:
528:
498:
468:
435:
424:on 6 June 2022
418:Bloomberg L.P.
402:
369:
344:
322:
296:
274:
263:on 3 July 2007
247:
245:
242:
233:
230:
191:
188:
184:with prejudice
164:
161:
153:
150:
104:
103:
100:medivation.com
96:
92:
91:
86:
82:
81:
72:
69:
66:
65:
62:
55:
53:
49:
48:
45:
41:
40:
35:
31:
30:
15:
13:
10:
9:
6:
4:
3:
2:
784:
773:
770:
768:
765:
763:
760:
758:
755:
753:
750:
748:
745:
743:
740:
738:
735:
733:
730:
728:
725:
723:
720:
719:
717:
706:
701:
700:
696:
689:
684:
681:
676:
670:
667:
662:
656:
653:
648:
644:
638:
635:
630:
626:
619:
616:
611:
605:
602:
597:
591:
588:
583:
577:
574:
571:
566:
563:
550:
546:
542:
538:
532:
529:
525:
512:
508:
502:
499:
495:
482:
478:
472:
469:
453:
446:
439:
436:
423:
419:
415:
409:
407:
403:
392:
388:
384:
380:
373:
370:
358:
354:
348:
345:
332:
326:
323:
310:
306:
300:
297:
284:
278:
275:
262:
258:
252:
249:
243:
241:
239:
231:
229:
227:
222:
220:
215:
213:
209:
205:
201:
197:
189:
187:
185:
182:
178:
173:
170:
162:
160:
158:
151:
149:
147:
143:
141:
137:
133:
129:
125:
120:
118:
117:San Francisco
114:
110:
101:
97:
93:
90:
87:
83:
80:
76:
73:
67:
63:United States
58:
57:San Francisco
54:
50:
46:
42:
39:
36:
32:
28:
23:
683:
669:
655:
646:
637:
628:
618:
604:
590:
576:
565:
553:. Retrieved
549:the original
540:
531:
522:
515:. Retrieved
511:the original
501:
492:
485:. Retrieved
481:the original
471:
459:. Retrieved
452:the original
438:
426:. Retrieved
422:the original
416:. New York:
394:. Retrieved
382:
372:
360:. Retrieved
356:
347:
335:. Retrieved
325:
313:. Retrieved
309:the original
299:
287:. Retrieved
285:. Medivation
277:
265:. Retrieved
261:the original
251:
235:
223:
216:
193:
174:
166:
157:Steve Gorlin
155:
144:
128:enzalutamide
121:
108:
107:
79:Steve Gorlin
59:, California
52:Headquarters
555:17 November
517:17 November
487:17 November
461:17 November
428:17 November
315:17 November
289:17 November
267:17 November
224:In August,
200:AstraZeneca
716:Categories
396:2017-12-20
362:23 October
244:References
238:David Hung
109:Medivation
75:David Hung
70:Key people
391:0099-9660
337:4 January
181:dismissed
140:docetaxel
524:disease.
494:disease.
124:Astellas
34:Industry
647:Reuters
219:Celgene
95:Website
44:Founded
752:Pfizer
389:
232:Awards
226:Pfizer
212:Sanofi
146:Pfizer
136:XTANDI
89:Pfizer
77:&
455:(PDF)
448:(PDF)
204:Amgen
196:Roche
85:Owner
557:2012
519:2012
489:2012
463:2012
430:2012
387:ISSN
364:2020
339:2017
317:2012
291:2012
269:2012
206:and
190:2016
47:2004
629:WSJ
718::
645:.
627:.
543:.
539:.
521:.
491:.
405:^
385:.
381:.
355:.
202:,
198:,
61:,
631:.
612:.
584:.
559:.
465:.
432:.
399:.
366:.
341:.
319:.
293:.
271:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
